Document Detail

Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.
MedLine Citation:
PMID:  20217447     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Efficacy and safety of irinotecan and cisplatin administration every 2 weeks (biweekly regimen) or 4 weeks (4-weekly regimen) in patients with pretreated unresectable or recurrent gastric cancer was retrospectively evaluated.
METHODS: Study patients comprised two cohorts: cohort 1, consisting of 31 patients received chemotherapy on a 4-weekly regimen; and cohort 2, consisting of 32 patients received chemotherapy on a biweekly regimen. In cohort 1, patients received irinotecan (70 mg/m(2)) on days 1 and 15 and cisplatin (80 mg/m(2)) on day 1 every 4 weeks; in cohort 2, patients received irinotecan (60 mg/m(2)) on day 1 and cisplatin (30 mg/m(2)) on day 1 every 2 weeks.
RESULTS: Response rates were for cohorts 1 and 2 were 26% (7/27) and 28% (7/25) in patients with measurable lesions, median progression-free survivals were 3.5 and 4.3 months, and median survival times after irinotecan and cisplatin initiation were 9.5 and 10.1 months, respectively. The incidence of grades 3 and 4 hematological toxicities in cohorts 1 and 2 were 74% and 44% for leukopenia, 81% and 53% for neutropenia, and 45% and 28% for anemia, respectively. Incidences of grades 3 and 4 nonhematological toxicities were 23% and 12% for nausea, 23% and 9% for vomiting, 19% and 12% for anorexia, and 6% and 6% for febrile neutropenia, respectively.
CONCLUSION: Irinotecan plus cisplatin chemotherapy administered on a biweekly regimen was comparable in efficacy to a 4-weekly regimen and might be more feasible than the 4-weekly regimen.
Takeshi Sakamoto; Hirofumi Yasui; Narikazu Boku; Yusuke Onozawa; Shuichi Hironaka; Akira Fukutomi; Kentaro Yamazaki; Keisei Taku; Nozomu Machida; Akiko Todaka; Hideharu Tomita; Takahiro Tsushima; Hiroya Taniguchi; Satoshi Hamauchi
Related Documents :
16575467 - Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer.
17630037 - Different strategies of sequential and combination chemotherapy for patients with poor ...
17414627 - Phase ii study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-li...
19246947 - Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and li...
2658537 - High-dose chemotherapy and autologous marrow transplantation for esthesioneuroblastoma ...
2990657 - Teratoma with malignant transformation in germ cell tumors in men.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2010-03-10
Journal Detail:
Title:  International journal of clinical oncology     Volume:  15     ISSN:  1437-7772     ISO Abbreviation:  Int. J. Clin. Oncol.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-06-14     Completed Date:  2010-09-27     Revised Date:  2012-12-13    
Medline Journal Info:
Nlm Unique ID:  9616295     Medline TA:  Int J Clin Oncol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  287-93     Citation Subset:  IM    
Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / drug therapy*,  mortality,  pathology,  radiography
Antineoplastic Agents, Phytogenic / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*,  adverse effects
Camptothecin / administration & dosage,  analogs & derivatives
Cisplatin / administration & dosage
Disease-Free Survival
Drug Administration Schedule
Kaplan-Meier Estimate
Middle Aged
Neoplasm Recurrence, Local / drug therapy*,  mortality
Retrospective Studies
Stomach Neoplasms / drug therapy*,  mortality,  pathology,  radiography
Time Factors
Tomography, X-Ray Computed
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 15663-27-1/Cisplatin; 7673326042/irinotecan; 7689-03-4/Camptothecin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Dots are not clots: the over-diagnosis and over-treatment of PE.
Next Document:  Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient ...